share_log

Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9

Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9

Stephens & Co.Lifecore Biomedical維持同等權重,目標價上調至9美元
Benzinga ·  2023/09/01 10:51

Stephens & Co. analyst Jacob Johnson maintains Lifecore Biomedical (NASDAQ:LFCR) with a Equal-Weight and raises the price target from $8 to $9.

Stephens&Co.分析師雅各布·約翰遜維持Lifecore Biomedical(納斯達克:LFCR)的同等權重,並將目標價從8美元上調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論